Current developments in thrombolytic therapy.
D000208:Acute Disease; D000925:Anticoagulants / Q000627:therapeutic use; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005342:Fibrinolysis; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000627:therapeutic use; D006801:Humans; D009203:Myocardial Infarction / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000188:drug therapy / Q000209:etiology; D011859:Radiography; D013300:Streptokinase / Q000009:adverse effects / Q000627:therapeutic use; D013923:Thromboembolism / Q000188:drug therapy; D013924:Thrombophlebitis / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D013927:Thrombosis / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use; D014689:Venous Insufficiency / Q000209:etiology
D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006493:Heparin; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator